Genmab A/S GMAB.CO Stock
Genmab A/S Price Chart
Genmab A/S GMAB.CO Financial and Trading Overview
| Genmab A/S stock price | 1832.5 DKK |
| Previous Close | 2625 DKK |
| Open | 2645 DKK |
| Bid | 2684 DKK x N/A |
| Ask | 2687 DKK x N/A |
| Day's Range | 2641 - 2689 DKK |
| 52 Week Range | 1888 - 3327 DKK |
| Volume | 13.03K DKK |
| Avg. Volume | 90.23K DKK |
| Market Cap | 175.28B DKK |
| Beta (5Y Monthly) | 0.683524 |
| PE Ratio (TTM) | 33.60861 |
| EPS (TTM) | 83.01 DKK |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3122.23 DKK |
GMAB.CO Valuation Measures
| Enterprise Value | 150.1B DKK |
| Trailing P/E | 33.60861 |
| Forward P/E | 30.125616 |
| PEG Ratio (5 yr expected) | 2.08 |
| Price/Sales (ttm) | 11.433564 |
| Price/Book (mrq) | 6.4430857 |
| Enterprise Value/Revenue | 9.791 |
| Enterprise Value/EBITDA | 22.535 |
Trading Information
Genmab A/S Stock Price History
| Beta (5Y Monthly) | 0.683524 |
| 52-Week Change | 32.14% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3327 DKK |
| 52 Week Low | 1888 DKK |
| 50-Day Moving Average | 2741.16 DKK |
| 200-Day Moving Average | 2790.95 DKK |
GMAB.CO Share Statistics
| Avg. Volume (3 month) | 90.23K DKK |
| Avg. Daily Volume (10-Days) | 88.04K DKK |
| Shares Outstanding | 65.26M |
| Float | 64.42M |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 49.71% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 34.46% |
| Operating Margin (ttm) | 41.21% |
| Gross Margin | 100.00% |
| EBITDA Margin | 43.45% |
Management Effectiveness
| Return on Assets (ttm) | 14.27% |
| Return on Equity (ttm) | 21.17% |
Income Statement
| Revenue (ttm) | 15.33B DKK |
| Revenue Per Share (ttm) | 234.61 DKK |
| Quarterly Revenue Growth (yoy) | 34.69% |
| Gross Profit (ttm) | 14.6B DKK |
| EBITDA | 6.66B DKK |
| Net Income Avi to Common (ttm) | 5.28B DKK |
| Diluted EPS (ttm) | 79.92 |
| Quarterly Earnings Growth (yoy) | -51.39% |
Balance Sheet
| Total Cash (mrq) | 24.54B DKK |
| Total Cash Per Share (mrq) | 376.31 DKK |
| Total Debt (mrq) | 829M DKK |
| Total Debt/Equity (mrq) | 3.05 DKK |
| Current Ratio (mrq) | 14.44 |
| Book Value Per Share (mrq) | 416.881 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 6.56B DKK |
| Levered Free Cash Flow (ttm) | 4.53B DKK |
Profile of Genmab A/S
| Country | Denmark |
| State | N/A |
| City | Copenhagen |
| Address | Kalvebod Brygge 43 |
| ZIP | 1560 |
| Phone | 45 70 20 27 28 |
| Website | https://www.genmab.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 1846 |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Q&A For Genmab A/S Stock
What is a current GMAB.CO stock price?
Genmab A/S GMAB.CO stock price today per share is 1832.5 DKK.
How to purchase Genmab A/S stock?
You can buy GMAB.CO shares on the Copenhagen exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Genmab A/S?
The stock symbol or ticker of Genmab A/S is GMAB.CO.
Which industry does the Genmab A/S company belong to?
The Genmab A/S industry is Biotechnology.
How many shares does Genmab A/S have in circulation?
The max supply of Genmab A/S shares is 65.2M.
What is Genmab A/S Price to Earnings Ratio (PE Ratio)?
Genmab A/S PE Ratio is 22.07565300 now.
What was Genmab A/S earnings per share over the trailing 12 months (TTM)?
Genmab A/S EPS is 83.01 DKK over the trailing 12 months.
Which sector does the Genmab A/S company belong to?
The Genmab A/S sector is Healthcare.
Genmab A/S GMAB.CO included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| OMX Copenhagen 20 OMXC20 | 2873.15 DKK 421.26 USD |
+0.34
|
— — | 2848.04 DKK 417.58 USD | 2892.8 DKK 424.15 USD | — - | — — |
| OMX_Nordic_Large_Cap_ISK_GI OMXNLCISKGI | 647.31 ISK 4.76 USD |
-0.76
|
— — | 644.86 ISK 4.74 USD | 655.05 ISK 4.82 USD | — - | — — |
| Nasdaq Developed Select Leaders NQDMSLC | 1260.81 USD — |
0
|
— — | 1243.71 USD — | 1264.94 USD — | — - | — — |
| OMX_Nordic_Large_Cap_DKK_GI OMXNLCDKKGI | 451.11 DKK 66.14 USD |
-0.75
|
— — | 449.8 DKK 65.95 USD | 456.45 DKK 66.93 USD | — - | — — |
| NASDAQ OMX Nordic 120 SEK Net I NOMXN120SEKNI | 2662.17 SEK 259.86 USD |
-0.48
|
— — | 2647.84 SEK 258.46 USD | 2685.78 SEK 262.17 USD | — - | — — |
| OMX Copenhagen_PI OMXCPI | 1990.73 DKK 291.88 USD |
+0.09
|
— — | 1976.83 DKK 289.84 USD | 2005.21 DKK 294.01 USD | — - | — — |
| NASDAQ OMX Nordic 120 Gross Ind NOMXN120GI | 2644.33 EUR 2890.61 USD |
-0.59
|
— — | 2634.46 EUR 2879.82 USD | 2672.76 EUR 2921.69 USD | — - | — — |
| OMX Copenhagen_GI OMXCGI | 3739.11 DKK 548.23 USD |
+0.09
|
— — | 3713 DKK 544.4 USD | 3766.31 DKK 552.22 USD | — - | — — |
| OMX Copenhagen Health Care PI CX20PI | 10582.85 DKK 1551.67 USD |
+0.84
|
— — | 10463.38 DKK 1534.15 USD | 10642.22 DKK 1560.37 USD | — - | — — |
| OMX Copenhagen Cap_GI OMXCCAPGI | 2848.59 DKK 417.66 USD |
-1.09
|
— — | 2847.64 DKK 417.52 USD | 2889.77 DKK 423.7 USD | — - | — — |
| OMX Copenhagen Benchmark_GI OMXCBGI | 4620.56 DKK 677.47 USD |
+0.24
|
— — | 4583.38 DKK 672.02 USD | 4650.53 DKK 681.87 USD | — - | — — |
| OMX Copenhagen Benchmark Cap_GI OMXCBCAPGI | 2765.46 DKK 405.47 USD |
-1.23
|
— — | 2765.46 DKK 405.47 USD | 2810.09 DKK 412.02 USD | — - | — — |
| OMX Copenhagen 20 CAP OMXC20CAP | 1835.4 DKK 269.11 USD |
<0.01
|
— — | 1835.4 DKK 269.11 USD | 1835.4 DKK 269.11 USD | — - | — — |
| OMX_Nordic_Large_Cap_SEK_GI OMXNLCSEKGI | 547.76 SEK 53.47 USD |
-0.65
|
— — | 545.17 SEK 53.22 USD | 553.26 SEK 54 USD | — - | — — |
| NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD | 2100.38 AUD 1390.15 USD |
<0.01
|
— — | 2100.38 AUD 1390.15 USD | 2100.38 AUD 1390.15 USD | — - | — — |
| OMX_Nordic_Large_Cap_EUR_GI OMXNLCEURGI | 450.93 EUR 492.92 USD |
-0.76
|
— — | 449.55 EUR 491.41 USD | 456.31 EUR 498.81 USD | — - | — — |
| NASDAQ OMX Nordic Health Care N NOMXNHCNI | 5834.73 EUR 6378.15 USD |
+0.21
|
— — | 5808.71 EUR 6349.7 USD | 5865.67 EUR 6411.96 USD | — - | — — |
| OMX Nordic 40 OMXN40 | 2896.92 EUR 3166.73 USD |
-0.47
|
— — | 2883.48 EUR 3152.04 USD | 2925.37 EUR 3197.83 USD | — - | — — |
| NASDAQ OMX Nordic 120 Net Index NOMXN120NI | 2460.84 EUR 2690.04 USD |
-0.59
|
— — | 2451.66 EUR 2679.99 USD | 2487.3 EUR 2718.95 USD | — - | — — |
| OMX_Copenhagen_Large_Cap_PI OMXCLCPI | 606.65 DKK 88.95 USD |
+0.13
|
— — | 602.27 DKK 88.31 USD | 610.9 DKK 89.57 USD | — - | — — |
- {{ link.label }} {{link}}